Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Baxalta will pay $105 million to genome-editing firm Precision BioSciences as part of a pact to develop off-the-shelf chimeric antigen receptor T-cell (CART) therapies for six cancer targets. The most advanced CART therapies have been highly personalized: Companies reengineer a patient’s own T cells to find and destroy cancer cells. Precision BioSciences’ genome-editing technology allows CARTs to be developed from healthy donors as treatments for multiple patients. The partners expect the first allogeneic CART therapy will enter the clinic late next year.
This article has been sent to the following recipient: